文献速递妇科

卡度尼利单抗联合化疗一线治疗晚期或复发性子宫内膜癌的II期试验中期分析

Efficacy and safety of cadonilimab combined with chemotherapy as first-line treatment for primary advanced or recurrent endometrial cancer: An interim analysis of a prospective, single-arm, open-label phase II trial.
PubMed 文献 · Gynecol Oncol · 2026-01-01

本研究为研究者发起的多中心、开放标签、单臂II期试验,纳入27例FIGO III/IV期或复发性子宫内膜癌患者,评估卡度尼利单抗联合铂类化疗的一线疗效与安全性。结果显示客观缓解率74.1%,疾病控制率96.3%,中位无进展生存期10.5个月,治疗相关不良事件以1-2级为主。

要点

  • 卡度尼利单抗联合化疗一线治疗晚期或复发性子宫内膜癌ORR达74.1%。
  • 中位PFS为10.5个月,12个月PFS率49.6%,12个月OS率90.2%。
  • dMMR肿瘤患者疾病进展风险低于pMMR患者,安全性可控。

核心结论

  • 卡度尼利单抗联合化疗一线治疗晚期或复发性子宫内膜癌显示出具有临床意义的抗肿瘤活性和可控的安全性。

研究设计与样本

  • 研究者发起的多中心、开放标签、单臂II期试验,纳入27例18-75岁组织学确诊的FIGO III/IV期或复发性子宫内膜癌患者。
  • 患者接受卡度尼利单抗10 mg/kg静脉每3周联合铂类化疗,后续卡度尼利单抗维持治疗。
  • 主要终点为按RECIST v1.1评估的客观缓解率,次要终点包括疾病控制率、缓解持续时间、无进展生存期、总生存期和安全性。

主要发现

  • 27例患者中客观缓解率为74.1%(95% CI,55.6%-87.3%),包括1例完全缓解(3.7%)和19例部分缓解(70.4%),疾病控制率96.3%。
  • 中位起效时间2.8个月,中位缓解持续时间17.8个月(95% CI,8.8-不可估计)。
  • 中位无进展生存期10.5个月(95% CI,8.2-不可估计),12个月无进展生存率49.6%;中位总生存期未达到,12个月总生存率90.2%。
  • 各亚组客观缓解率总体一致,dMMR肿瘤患者疾病进展风险低于pMMR患者。
  • 治疗相关不良事件发生率77.8%,以1-2级为主;≥3级事件发生率18.5%,无治疗相关死亡。

临床怎么用

  • 该联合方案可作为晚期或复发性子宫内膜癌一线治疗的候选方案,尤其需关注分子分型对疗效的影响。

局限性

  • 本结果为单臂II期试验的中期分析,样本量27例,缺乏随机对照,结论需进一步验证。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: To assess the interim efficacy and safety of cadonilimab, a PD-1/CTLA-4 bispecific antibody, in combination with platinum-based chemotherapy as first-line treatment for patients with primary advanced or recurrent endometrial cancer (EC), with exploratory analyses by molecular subgroups. METHODS: This investigator-initiated, multicenter, open-label, single-arm phase II trial enrolled women aged 18-75 years with histologically confirmed FIGO stage III/IV or recurrent EC. Patients received cadonilimab (10 mg/kg intravenously every 3 weeks) combined with platinum-based chemotherapy, followed by cadonilimab maintenance. The primary endpoint was objective response rate (ORR) assessed per RECIST v1.1. Secondary endpoints included disease control rate (DCR), duration of response (DoR), progression-free survival (PFS), overall survival (OS), and safety. Exploratory analyses were performed according to PD-L1 expression, mismatch repair (MMR) status, and molecular subtype. This interim analysis was conducted after 27 efficacy-evaluable patients reached the predefined PFS milestone. RESULTS: Among 27 patients, ORR was 74.1% (95% CI, 55.6%-87.3%), including one complete response (3.7%) and 19 partial responses (70.4%), with a DCR of 96.3%. Median time to response was 2.8 months, and median DoR was 17.8 months (95% CI, 8.8-not estimable). Median PFS was 10.5 months (95% CI, 8.2-not estimable), with a 12-month PFS rate of 49.6%. Median OS was not reached; the 12-month OS rate was 90.2%. ORR was generally consistent across subgroups, while patients with dMMR tumors showed a lower risk of disease progression compared with those with pMMR tumors. Treatment-related adverse events occurred in 77.8% of patients, predominantly grade 1-2; grade ≥ 3 events occurred in 18.5%, with no treatment-related deaths. CONCLUSIONS: Cadonilimab combined with chemotherapy demonstrated clinically meaningful activity and manageable safety as first-line treatment for advanced or recurrent EC, supporting further investigation, particularly in molecularly defined populations.

来源:Gynecol Oncol,查看原文。版权归原作者所有。

引用

  1. Liu B, Chen J, Chen L, et al. Efficacy and safety of cadonilimab combined with chemotherapy as first-line treatment for primary advanced or recurrent endometrial cancer: An interim analysis of a prospective, single-arm, open-label phase II trial. Gynecol Oncol. 2026. PMID: 42000370. doi:10.1016/j.ygyno.2026.03.014

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。